These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 8674065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H, Baril P, Tabone E, Bérard F, Sanhadji K, Balme B, Wolf F, Perrot H, Thomas L.
    Cancer Res; 2000 Oct 15; 60(20):5848-56. PubMed ID: 11059782
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells.
    Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M.
    Oncogene; 1997 Oct 23; 15(17):2069-75. PubMed ID: 9366524
    [Abstract] [Full Text] [Related]

  • 9. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M.
    Cancer Res; 1989 Sep 15; 49(18):5091-6. PubMed ID: 2548711
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, Landthaler M, McClelland M.
    Clin Cancer Res; 1998 Mar 15; 4(3):791-7. PubMed ID: 9533549
    [Abstract] [Full Text] [Related]

  • 12. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression.
    Rak JW, Hegmann EJ, Lu C, Kerbel RS.
    J Cell Physiol; 1994 May 15; 159(2):245-55. PubMed ID: 8163565
    [Abstract] [Full Text] [Related]

  • 13. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
    Doucet C, Meazza R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, Ferrini S, Alileche A, Taoufik Y, Jasmin C, Azzarone B, Indiveri F.
    Melanoma Res; 1997 Aug 15; 7 Suppl 2():S7-17. PubMed ID: 9578412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Multiple human chromosomes carrying tumor-suppressor functions for the mouse melanoma cell line B16-F10, identified by microcell-mediated chromosome transfer.
    Kugoh H, Nakamoto H, Inoue J, Funaki K, Barrett JC, Oshimura M.
    Mol Carcinog; 2002 Nov 15; 35(3):148-56. PubMed ID: 12410566
    [Abstract] [Full Text] [Related]

  • 16. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
    Ren S, Smith MJ, Louro ID, McKie-Bell P, Bani MR, Wagner M, Zochodne B, Redden DT, Grizzle WE, Wang Nd, Smith DI, Herbst RA, Bardenheuer W, Opalka B, Schütte J, Trent JM, Ben-David Y, Ruppert JM.
    Oncogene; 2000 Mar 09; 19(11):1419-27. PubMed ID: 10723133
    [Abstract] [Full Text] [Related]

  • 17. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
    Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M.
    Oncogene; 1996 Dec 05; 13(11):2339-47. PubMed ID: 8957075
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.
    McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Lev DC, Bar-Eli M.
    Clin Cancer Res; 2003 Dec 15; 9(17):6560-6. PubMed ID: 14695161
    [Abstract] [Full Text] [Related]

  • 20. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.
    Cancer J; 2000 Dec 15; 6(4):220-33. PubMed ID: 11038142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.